Role of carnitine in modulating acute-phase protein synthesis in hemodialysis patients.
Increased serum levels of C-reactive protein (CRP) in uremic and dialysis patients are associated with low serum prealbumin and albumin concentrations and increased mortality and greater risk of cardiovascular disease. Proinflammatory cytokines may cause malnutrition by increasing protein catabolism. Many studies have shown that L-carnitine supplementation leads to improvements in several conditions seen in uremic patients, including cardiac complications, impaired exercise and functional capacities, muscle symptoms, increased symptomatic intradialytic hypotension, and erythropoietin-resistant anemia. L-carnitine therapy may either suppress the inflammatory response or act independently on both inflammation and appetite and/or anabolic processes. Moreover, L-carnitine may suppress proinflammatory cytokines in sick individuals without renal disease and may improve protein synthesis or nitrogen balance in patients without renal disease and in hemodialysis and peritoneal dialysis patients. In a pilot study, we provided preliminary evidence that treatment with L-carnitine, 20 mg/kg 3 times weekly at the end of each hemodialysis treatment, was associated with a reduction in serum CRP levels and improvement in anabolic status. The improvement or normalization of serum concentrations of serum CRP also was correlated with increased serum concentrations of albumin, transferrin, and blood hemoglobin. The possibility that some or all of these changes may have been caused by improved nutritional intake cannot be ruled out. Further randomized clinical trials will be necessary to confirm the role of L-carnitine as a modulator of inflammatory protein synthesis in hemodialysis patients.
Bellinghieri
Guido
G
Department of Medicine and Pharmacology, Division of Nephrology, University of Messina, Messina, Italy.
Santoro
Domenico
D
Calvani
Menotti
M
Savica
Vincenzo
V
D000209:Acute-Phase Proteins / Q000096:biosynthesis*; D002097:C-Reactive Protein / Q000032:analysis; D002331:Carnitine / Q000008:administration & dosage / Q000097:blood / Q000502:physiology*; D004734:Energy Metabolism; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000150:complications / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D044342:Malnutrition / Q000209:etiology; D006435:Renal Dialysis / Q000009:adverse effects*; D012709:Serum Albumin / Q000032:analysis; D014168:Transferrin / Q000032:analysis; D014511:Uremia / Q000097:blood / Q000150:complications / Q000628:therapy
D000209:Acute-Phase Proteins; D006454:Hemoglobins; D012709:Serum Albumin; D014168:Transferrin; D002097:C-Reactive Protein; D002331:Carnitine